#1 Clinical Trials Search in Europe

Lasofoxifene

Lasofoxifene is an investigational drug being studied in clinical trials for its potential in treating various conditions, primarily breast cancer and osteoporosis. This article summarizes key findings from several clinical trials evaluating the safety and efficacy of lasofoxifene in different patient populations and treatment regimens.

Table of Contents

What is Lasofoxifene?

Lasofoxifene is a medication that belongs to a class of drugs called Selective Estrogen Receptor Modulators (SERMs). SERMs are compounds that can act like estrogen in some parts of the body while blocking estrogen’s effects in others. Lasofoxifene was developed to treat various conditions related to estrogen deficiency or hormonal imbalances[1].

This drug is also known by its brand name AZU-101 when used in certain formulations[5]. It’s important to note that lasofoxifene is still being studied in clinical trials and may not be widely available for all treatments mentioned in this article.

What Conditions Does Lasofoxifene Treat?

Lasofoxifene has been studied for several medical conditions, including:

  • Osteoporosis: This is a condition where bones become weak and brittle, increasing the risk of fractures. Lasofoxifene has shown promise in preventing and treating osteoporosis in postmenopausal women[1][2].
  • Breast Cancer: Specifically, lasofoxifene is being investigated for treating advanced or metastatic estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer in patients who have developed mutations in the estrogen receptor 1 (ESR1) gene[3].
  • Postmenopausal Symptoms: Some studies are exploring the use of lasofoxifene for managing symptoms associated with menopause, such as vaginal dryness and atrophy[5].

How Does Lasofoxifene Work?

Lasofoxifene works by selectively interacting with estrogen receptors in different tissues of the body. Here’s how it affects various conditions:

  • For Osteoporosis: In bone tissue, lasofoxifene mimics the effects of estrogen, helping to increase bone mineral density (BMD). This can help prevent bone loss and reduce the risk of fractures in postmenopausal women[1].
  • For Breast Cancer: In breast tissue, particularly in cases where the cancer has developed resistance to other treatments due to ESR1 mutations, lasofoxifene may help block the growth-promoting effects of estrogen on cancer cells[3].
  • For Postmenopausal Symptoms: In vaginal tissue, lasofoxifene may help improve symptoms like dryness and discomfort by having estrogen-like effects[5].

How is Lasofoxifene Administered?

The administration of lasofoxifene can vary depending on the condition being treated and the specific study or treatment protocol. Here are some common methods:

  • Oral Tablets: For osteoporosis treatment and prevention, lasofoxifene is often given as daily oral tablets. Doses studied have ranged from 0.25 mg to 0.5 mg per day[1][2].
  • Vaginal Formulation: For treating postmenopausal symptoms, a vaginal formulation of lasofoxifene (AZU-101) is being studied. This involves much lower doses, ranging from 0.1 μg to 1 μg, administered either weekly or twice weekly[5].
  • Higher Oral Doses for Cancer: In breast cancer studies, higher oral doses of 5 mg per day are being investigated[3].

Lasofoxifene in Clinical Trials

Lasofoxifene has been the subject of several clinical trials, each focusing on different aspects of its potential benefits:

  • Osteoporosis Studies: Large trials like the PEARL (Postmenopausal Evaluation and Risk-reduction with Lasofoxifene) study have investigated lasofoxifene’s effectiveness in reducing new spinal fractures in women with osteoporosis[2].
  • Breast Cancer Research: Ongoing studies are comparing lasofoxifene to existing treatments like fulvestrant in patients with advanced breast cancer who have ESR1 mutations[3].
  • Combination Therapies: Some trials are exploring the use of lasofoxifene in combination with other drugs, such as abemaciclib, for treating advanced breast cancer[6].
  • Postmenopausal Symptom Management: Studies are underway to evaluate the safety and efficacy of vaginal lasofoxifene for treating symptoms like vaginal dryness in postmenopausal women[5].

Potential Side Effects and Safety

As with any medication, lasofoxifene may cause side effects. The full safety profile is still being established through clinical trials, but some potential side effects and safety considerations include:

  • Common Side Effects: These may include hot flashes, muscle spasms, and vaginal discharge[2].
  • Cardiovascular Effects: Some studies have monitored for potential impacts on heart health[2].
  • Gynecological Safety: Researchers are carefully evaluating any effects on the uterus and other reproductive organs[2].
  • Long-term Safety: Ongoing studies are assessing the long-term safety of lasofoxifene, particularly when used for extended periods in osteoporosis prevention[4].

It’s important to note that the safety profile may differ depending on the dose, route of administration, and condition being treated. Always consult with a healthcare provider about potential risks and benefits.

Future Research and Potential Applications

The research on lasofoxifene is ongoing, with several exciting areas of investigation:

  • Expanded Cancer Applications: Researchers are exploring lasofoxifene’s potential in treating other hormone-sensitive cancers[3].
  • Combination Therapies: Studies are investigating how lasofoxifene works in combination with other drugs, potentially offering more effective treatment options for certain conditions[6].
  • Personalized Medicine: As our understanding of genetic factors in disease grows, lasofoxifene may play a role in more targeted, personalized treatment approaches, especially in breast cancer care[3].
  • Quality of Life Improvements: Ongoing research is focusing on how lasofoxifene might improve overall quality of life for postmenopausal women, addressing multiple symptoms and health concerns[5].

As research progresses, we may see lasofoxifene approved for new indications or used in innovative ways to improve patient care across multiple conditions.

Trial Focus Key Findings Patient Population Dosage
Osteoporosis Prevention Increased BMD in spine and hip Postmenopausal women 0.25 mg – 0.5 mg daily
Advanced ER+/HER2- Breast Cancer Evaluation of PFS compared to fulvestrant Pre- and postmenopausal women with ESR1 mutations 5 mg daily
Combination Therapy Safety and efficacy with abemaciclib Advanced or metastatic ER+/HER2- breast cancer 5 mg daily
Vaginal Formulation Safety, PK, and efficacy for postmenopausal symptoms Postmenopausal women 0.1 μg – 1 μg weekly or twice-weekly
Neoadjuvant Breast Cancer Part of I-SPY trial for personalized treatment Various breast cancer subtypes Not specified

FAQ

  • What is lasofoxifene and how does it work? Lasofoxifene is a selective estrogen receptor modulator (SERM). It works by binding to estrogen receptors in the body, potentially helping to prevent and treat conditions like osteoporosis and certain types of breast cancer that are influenced by estrogen.
  • What conditions is lasofoxifene being studied for in clinical trials? Lasofoxifene is being investigated primarily for the treatment of osteoporosis in postmenopausal women and for advanced or metastatic estrogen receptor-positive (ER+) breast cancer, especially in patients with ESR1 mutations.
  • How is lasofoxifene administered in these clinical trials? In the trials reviewed, lasofoxifene is typically administered orally. Dosages vary by study, ranging from 0.25 mg to 5 mg daily, depending on the condition being treated and the specific trial protocol.
  • What are some potential side effects of lasofoxifene? While specific side effects are not detailed in the provided trial summaries, as with any medication, lasofoxifene may have side effects. These are carefully monitored in clinical trials through safety assessments, including adverse event reporting and laboratory tests.
  • Are there any promising results from lasofoxifene clinical trials? Several trials show promising results for lasofoxifene in increasing bone mineral density for osteoporosis prevention and potentially treating advanced breast cancer, especially in patients with ESR1 mutations. However, more research is needed to fully establish its efficacy and safety profile.

Ongoing Clinical Trials on Lasofoxifene

  • Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Hungary Italy Poland +2

Glossary

  • Lasofoxifene: A selective estrogen receptor modulator (SERM) being investigated for the treatment of osteoporosis and breast cancer.
  • Estrogen Receptor Positive (ER+): A type of breast cancer that grows in response to the hormone estrogen.
  • HER2-negative: Breast cancer cells that do not have a high amount of a protein called HER2 on their surface.
  • ESR1 mutation: A mutation in the estrogen receptor gene that can lead to resistance to some forms of hormone therapy in breast cancer.
  • Bone Mineral Density (BMD): A measure of bone density used to diagnose osteoporosis and assess the risk of fractures.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Pathologic Complete Response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually before surgery in cancer treatment.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT00143273
  2. https://clinicaltrials.gov/study/NCT00141323
  3. https://clinicaltrials.gov/study/NCT03781063
  4. https://clinicaltrials.gov/study/NCT00674453
  5. https://clinicaltrials.gov/study/NCT06197568
  6. https://clinicaltrials.gov/study/NCT04432454